The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial

Scanlon, Peter H ORCID: 0000-0001-8513-710X, Loftus, J, Starita, C. and Stratton, I M (2015) The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial. Diabetic Medicine, 32 (1). pp. 97-101. doi:10.1111/dme.12593

Preview

Text (OnlineOpen Published version) The use of weighted health-related quality of life scores.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives 4.0. Download (64kB) | Preview

Abstract

Aims To examine the relationship between visual acuity in each eye and Quality of Life (QoL) outcomes in people with diabetic macular oedema. Methods Cross sectional retrospective analysis of data collected at baseline in 289 people entered into a randomized clinical trial with diabetic macular oedema which investigated the safety and efficacy of a vascular endothelial growth factor inhibitor, pegaptanib sodium. At the baseline visit, visual acuity was measured through refraction and using retro-illuminated modified Early Treatment Diabetic Retinopathy Study Log MAR charts, and patient health-related QoL was determined using the European Quality of Life EQ–5D–3L and the Visual Functioning Questionnaire–25 (NEI–VFQ25). A regression analysis with QoL score from each vision-related domain as the dependent variable was fitted using linear and quadratic terms of the better and worse eye, age, gender, adjusted for number of concurrent conditions, ethnicity and level of diabetes control. Results For all vision-related QoL domains from NEI–VFQ25 and EQ–5D–3L except ocular pain, both visual acuity in the better-seeing and the worse-seeing eye gave a significant increase in correlation coefficient over that obtained from clinical and demographic data. The NEI–VFQ25 correlation was most closely associated with a weighted visual acuity measure of 0.75 in the better and 0.25 in the worse eye or 0.60 in the better and 0.40 in the worse eye. Conclusions We recommend that a weighted visual acuity measure from both eyes is considered in future diabetic macular oedema trials.

Item Type:	Article
Article Type:	Article
Additional Information:	OnlineOpen funded article
Uncontrolled Keywords:	Quality of life, diabetes, diabetic macular oedema
Related URLs:	Publisher
Subjects:	R Medicine > RA Public aspects of medicine > RA645.A-Z Individual diseases or groups of diseases, A-Z > RA645.D54 Diabetes R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RE Ophthalmology
Divisions:	Schools and Research Institutes > School of Education and Science
Research Priority Areas:	Health, Life Sciences, Sport and Wellbeing
Depositing User:	Susan Turner
Date Deposited:	07 Jun 2015 17:58
Last Modified:	31 Aug 2023 09:09
URI:	https://eprints.glos.ac.uk/id/eprint/2333

Available Versions of this Item

• The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial [post print ie post peer review version]. (deposited 07 Jun 2015 15:22)
  • The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial. (deposited 07 Jun 2015 17:58) [Currently Displayed]

University Staff: Request a correction | Repository Editors: Update this record